Per- and polyfluoroalkyl substance (PFAS) exposure, maternal metabolomic perturbation, and fetal growth in African American women: A meet-in-the-middle approach
- PMID: 34735953
- PMCID: PMC8688254
- DOI: 10.1016/j.envint.2021.106964
Per- and polyfluoroalkyl substance (PFAS) exposure, maternal metabolomic perturbation, and fetal growth in African American women: A meet-in-the-middle approach
Abstract
Background: Prenatal exposures to per- and polyfluoroalkyl substances (PFAS) have been linked to reduced fetal growth. However, the detailed molecular mechanisms remain largely unknown. This study aims to investigate biological pathways and intermediate biomarkers underlying the association between serum PFAS and fetal growth using high-resolution metabolomics in a cohort of pregnant African American women in the Atlanta area, Georgia.
Methods: Serum perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and perfluorononanoic acid (PFNA) measurements and untargeted serum metabolomics profiling were conducted in 313 pregnant African American women at 8-14 weeks gestation. Multiple linear regression models were applied to assess the associations of PFAS with birth weight and small-for-gestational age (SGA) birth. A high-resolution metabolomics workflow including metabolome-wide association study, pathway enrichment analysis, and chemical annotation and confirmation with a meet-in-the-middle approach was performed to characterize the biological pathways and intermediate biomarkers of the PFAS-fetal growth relationship.
Results: Each log2-unit increase in serum PFNA concentration was significantly associated with higher odds of SGA birth (OR = 1.32, 95% CI 1.07, 1.63); similar but borderline significant associations were found in PFOA (OR = 1.20, 95% CI 0.94, 1.49) with SGA. Among 25,516 metabolic features extracted from the serum samples, we successfully annotated and confirmed 10 overlapping metabolites associated with both PFAS and fetal growth endpoints, including glycine, taurine, uric acid, ferulic acid, 2-hexyl-3-phenyl-2-propenal, unsaturated fatty acid C18:1, androgenic hormone conjugate, parent bile acid, and bile acid-glycine conjugate. Also, we identified 21 overlapping metabolic pathways from pathway enrichment analyses. These overlapping metabolites and pathways were closely related to amino acid, lipid and fatty acid, bile acid, and androgenic hormone metabolism perturbations.
Conclusion: In this cohort of pregnant African American women, higher serum concentrations of PFOA and PFNA were associated with reduced fetal growth. Perturbations of biological pathways involved in amino acid, lipid and fatty acid, bile acid, and androgenic hormone metabolism were associated with PFAS exposures and reduced fetal growth, and uric acid was shown to be a potential intermediate biomarker. Our results provide opportunities for future studies to develop early detection and intervention for PFAS-induced fetal growth restriction.
Keywords: Biomarkers; Fetal growth; High-resolution metabolomics; PFAS.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


References
-
- Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, Nakayama S, Lindstrom AB, Strynar MJ, & Lau C (2007). Perfluorooctanoic Acid–Induced Developmental Toxicity in the Mouse is Dependent on Expression of Peroxisome Proliferator–Activated Receptor-alpha. Toxicological Sciences, 98(2), 571–581. 10.1093/toxsci/kfm110 - DOI - PubMed
-
- Alderete TL, Jin R, Walker DI, Valvi D, Chen Z, Jones DP, Peng C, Gilliland FD, Berhane K, Conti DV, Goran MI, & Chatzi L (2019). Perfluoroalkyl substances, metabolomic profiling, and alterations in glucose homeostasis among overweight and obese Hispanic children: A proof-of-concept analysis. Environment International, 126, 445–453. 10.1016/j.envint.2019.02.047 - DOI - PMC - PubMed
-
- American College of Obstetricians and Gynecologists. (2014). Committee opinion no 611: method for estimating due date. Obstet Gynecol, 124(4), 863–866. 10.1097/01.A0G.0000454932.15177.be - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 NR014800/NR/NINR NIH HHS/United States
- U2C ES026542/ES/NIEHS NIH HHS/United States
- P50 ES026071/ES/NIEHS NIH HHS/United States
- U24 ES026539/ES/NIEHS NIH HHS/United States
- R01 MD009064/MD/NIMHD NIH HHS/United States
- UH3 OD023318/OD/NIH HHS/United States
- R01 MD009746/MD/NIMHD NIH HHS/United States
- R21 ES032117/ES/NIEHS NIH HHS/United States
- U2C ES026560/ES/NIEHS NIH HHS/United States
- U2C OD023375/OD/NIH HHS/United States
- P30 ES019776/ES/NIEHS NIH HHS/United States
- R24 ES029490/ES/NIEHS NIH HHS/United States
- U24 ES029490/ES/NIEHS NIH HHS/United States
- UG3 OD023318/OD/NIH HHS/United States
LinkOut - more resources
Full Text Sources